Trust signals
- Written by the FormBlends Medical Team, reviewed against primary literature from PubMed and ClinicalTrials.gov
- All major claims graded by evidence type in the ledger table below
- No sponsored rankings, no affiliate links to the compounds discussed
- Updated: 2026-05-29
Key Takeaways
- Enclomiphene raises total testosterone into the normal adult male range within 3-6 weeks in RCTs while preserving spermatogenesis, a documented advantage over TRT.
- GH-releasing peptides (e.g., CJC-1295, ipamorelin) raise GH pulse amplitude measurably but produce body composition changes of roughly 1-2 kg lean mass over months in human trials, not dramatic transformations.
- At approximately 2 IU recombinant HGH per day, clinical GHD replacement trials document visceral fat reduction and modest lean mass accrual over 6-12 months, but these trials enrolled growth-hormone-deficient patients, not healthy adults.
- Peptide degradation before injection is the single most underreported failure mode: poor sourcing or reconstitution produces a pharmacologically inert vial that looks identical to potent product.
- Social-media before-and-after photos are confounded by diet, training, other compounds, lighting, and selection bias and have no evidentiary value on their own.
What do enclomiphene before and after results actually look like?
In controlled trials, enclomiphene citrate raises total testosterone from hypogonadal levels (below 300 ng/dL) into the normal adult male range within 3-6 weeks, with LH and FSH rising within days. Subjective improvements in libido, mood, and energy lag lab values by weeks. Body composition changes are secondary and modest unless the baseline deficit was severe.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Evidence Ledger: Every Major Claim Graded
- How Enclomiphene Works and What That Predicts About Results
- Enclomiphene Before and After: Realistic Timelines
- What Do Peptide Injections Before and After Actually Show?
- 2 IU HGH Per Day Results: What the Clinical Data Shows
- What Most Pages Get Wrong About Peptide and HGH Results
- Why Peptides Degrade: The Chemistry Behind Storage Rules
- Honest Head-to-Head: Enclomiphene vs. TRT vs. Peptides vs. Anavar
- Operational Guide: How to Read a COA and Judge a Product
- Frequently Asked Questions
- Sources
Evidence Ledger: Every Major Claim Graded
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Enclomiphene raises total testosterone in hypogonadal men | Phase II/III RCTs (Wiehle et al.; Kim et al.) | Strong positive; normalizes T in majority of subjects | High |
| Enclomiphene preserves spermatogenesis vs. TRT | RCT with semen analysis endpoints | Positive (semen parameters maintained) | High |
| CJC-1295 raises GH pulse amplitude | Small human PK/PD studies | Positive; dose-dependent GH and IGF-1 rise | Moderate |
| GH secretagogues improve body composition | Small RCTs, mostly older adults or GHD subjects | Modest positive; ~1-2 kg lean, small fat reduction | Moderate (in target populations); Low in healthy adults |
| 2 IU/day recombinant HGH improves body comp in GHD adults | RCTs in GHD populations (GH Research Society guidelines) | Positive for visceral fat, lean mass, lipids | High in GHD; Low in healthy adults |
| Social-media before-and-after photos reflect compound efficacy | Anecdote / no controlled design | Unreliable; confounded | Very Low |
| Enclomiphene improves libido and energy | RCT symptom endpoints (ADAM questionnaire) | Positive but smaller and more variable than lab T improvements | Moderate |
| Peptide purity from research vendors is consistent | Third-party HPLC audits (intermittent, not systematic) | Highly variable; some products fail purity thresholds | Moderate (that variability exists) |
How Enclomiphene Works and What That Predicts About Results
Enclomiphene is the trans-isomer of clomiphene citrate. It acts as an estrogen receptor antagonist specifically at the hypothalamus and pituitary, blocking the negative feedback that endogenous estradiol normally exerts on GnRH and gonadotropin release.
The functional result is a rise in LH and FSH within 24-72 hours of the first dose. LH drives Leydig cell testosterone production; FSH maintains Sertoli cell function and spermatogenesis. Because the signal to the testes is upstream and endogenous, testicular volume and sperm production are maintained rather than suppressed, which is the pharmacological reason enclomiphene differs from exogenous testosterone.
What this mechanism does NOT prove: raising LH and testosterone does not automatically translate to symptom resolution. Androgen receptor sensitivity, co-existing thyroid disease, sleep apnea, and psychological factors all modulate whether a man feels better after testosterone normalization. Lab improvement is a necessary but not sufficient predictor of subjective before-and-after outcomes.
Enclomiphene Before and After: Realistic Timelines
| Timepoint | Expected Lab Change | Expected Subjective Change | Evidence Basis |
|---|---|---|---|
| Days 3-7 | LH and FSH measurably elevated | None or minimal | PK/PD data from Wiehle et al. Phase II trial |
| Weeks 3-6 | Total testosterone reaches new steady state, often 400-600+ ng/dL from sub-300 baseline | Some men notice early libido improvement | RCT data (Kim et al., 2013; Wiehle et al., 2014) |
| Weeks 6-12 | T stable; estradiol may rise proportionally | Energy, mood, libido more commonly reported as improved | ADAM symptom endpoints in RCTs |
| Months 3-6 | Body composition changes possible if baseline was severely hypogonadal | More sustained symptom relief expected if T remains normalized | Mechanism-based inference; limited long-term RCT data |
A practical note: enclomiphene's effect requires the testes to be functional. In primary hypogonadism (testicular failure), LH is already high and enclomiphene produces no meaningful testosterone rise.
What Do Peptide Injections Before and After Actually Show?
The category "peptides" covers wildly different mechanisms. The most searched before-and-after results involve GH-axis peptides (CJC-1295, ipamorelin, sermorelin, tesamorelin) and, to a lesser degree, body-repair peptides (BPC-157, TB-500). These are not interchangeable.
GH Secretagogues (CJC-1295, Ipamorelin, Sermorelin)
These peptides stimulate endogenous GH release by acting on GHRH receptors (CJC-1295, sermorelin) or ghrelin receptors (ipamorelin, MK-677). Human studies show measurable rises in overnight GH pulse amplitude and downstream IGF-1. Early human pharmacokinetic and pharmacodynamic work on CJC-1295 documented dose-dependent increases in GH and IGF-1 in healthy adults, establishing the basis for subsequent investigation. Body composition data from GH secretagogue trials generally shows modest effects: lean mass increases and fat reduction on the order of 1-2 kg over 3-6 months in older or GHD populations. In young, healthy, well-trained individuals, effects are smaller.
Tesamorelin
Tesamorelin is FDA-approved for HIV-associated lipodystrophy. Its before-and-after data is the strongest in the peptide class: FDA approval was based on RCTs showing significant visceral adipose tissue reduction (roughly 15-18% vs. placebo) over 6 months. This is disease-specific data; extrapolation to healthy adults is not supported.
BPC-157 and TB-500
Animal and in vitro data suggest wound-healing and anti-inflammatory effects. There are no published human RCTs for these compounds as of mid-2026. Before-and-after claims for these in humans are mechanism-based extrapolation or anecdote.
2 IU HGH Per Day Results: What the Clinical Data Shows
Recombinant human growth hormone (rhGH) at approximately 1-2 IU/day is the standard adult GHD replacement range per the GH Research Society consensus guidelines. In this population:
- Visceral adipose tissue decreases measurably over 6-12 months
- Lean body mass increases modestly
- Lipid profiles improve (LDL reduction, HDL increase reported in meta-analyses)
- Quality-of-life scores improve in GHD-specific instruments
What this does NOT mean for healthy adults: the same dose in a person with normal GH production produces supraphysiologic IGF-1 levels and carries risks including insulin resistance, fluid retention, arthralgias, and potential long-term cancer risk concerns from sustained IGF-1 elevation. The clinical before-and-after picture for 2 IU/day rhGH in healthy adults is not well-characterized by rigorous trials because few such trials exist, and off-label use does not have regulatory safety support.
What Most Pages Get Wrong About Peptide and HGH Results
The Degradation Problem: Your Vial May Already Be Inert
This is the single most underreported failure mode in before-and-after discussions. Peptides are short amino acid chains held together by peptide bonds. Those bonds are cleaved by:
- Enzymatic activity: even trace bacterial contamination produces proteases that destroy peptide structure
- Hydrolysis: once reconstituted in aqueous solution, peptides are in a hydrolysis-prone environment; rate accelerates with heat and oxidative conditions
- Oxidation: methionine and tryptophan residues are oxidized by dissolved oxygen, altering receptor-binding geometry
A person who sees no results after 8 weeks of injections may be injecting bacteriostatic water with fragments. They attribute the failure to protocol when the product never had potency. Third-party HPLC testing of research-chemical peptide products has repeatedly found significant purity variation across vendors. Without a COA from an independent lab, potency is unknown.
The Population Mismatch Problem
Most positive before-and-after data comes from GH-deficient, hypogonadal, aging, or HIV-positive populations. The deficit-correction effect is largest when baseline is lowest. A 30-year-old with normal hormone levels using the same compounds has far less physiological headroom. Results will be smaller. Commodity pages do not make this distinction.
The Confounding Problem in Transformation Photos
A person who starts a peptide protocol often simultaneously improves diet, increases training volume, improves sleep, and adds other compounds. The before photo is taken with poor lighting, slightly out of shape. The after photo is taken after a cut, in good light, pumped from a workout. The peptide may have contributed minimally or not at all to the visual change.
Why Peptides Degrade: The Chemistry Behind Storage Rules
Why lyophilized (freeze-dried) peptides store longer than reconstituted peptides: in powder form, there is no aqueous medium for hydrolysis to proceed. Peptide bonds require a water molecule to cleave. Removing water dramatically slows bond cleavage. Once you add bacteriostatic water, the clock starts.
Why storage at 2-8 degrees C matters for reconstituted peptides: hydrolysis and oxidation reaction rates follow Arrhenius kinetics; lower temperature reduces reaction rate. A reconstituted GH-releasing peptide left at room temperature degrades orders of magnitude faster than one kept refrigerated. This is not a conservative suggestion; it is basic reaction-rate chemistry.
Why repeated freeze-thaw cycles damage peptides: ice crystal formation during freezing physically disrupts secondary structure and creates localized concentration gradients that accelerate aggregation. The peptide sequence may be intact but the three-dimensional conformation needed for receptor binding is disrupted.
Why mixing with acidic solutions matters: many peptides are stable in mildly acidic pH and degrade faster at neutral or alkaline pH. This is why acetic acid (0.6% or 1%) rather than plain water is specified for certain peptides. If a peptide requiring acidic reconstitution is dissolved in plain bacteriostatic water (pH ~5.5-6.5 depending on lot), degradation accelerates. Read the specific reconstitution guidance for each peptide, not a generic protocol.
Honest Head-to-Head: Enclomiphene vs. TRT vs. GH Peptides vs. Anavar
| Factor | Enclomiphene | TRT (Testosterone) | GH Secretagogue Peptides | Anavar (Oxandrolone) |
|---|---|---|---|---|
| Evidence quality for T normalization | High (RCTs) | High (decades of RCTs) | N/A (not T-raising directly) | High (anabolic effect well documented) |
| Body composition effect (lean mass) | Modest, secondary to T rise | Moderate to strong | Modest (1-2 kg in trials) | Strong (strongest in this table) |
| Fertility/spermatogenesis | Preserved (advantage) | Suppressed (disadvantage) | Not affected | Suppressed at doses that produce results |
| HPG axis suppression | None (stimulates axis) | Complete suppression | None | Significant at effective doses |
| Hepatotoxicity risk | Low (oral, non-17aa) | Low (injectable forms) | Low | Real (17-alpha alkylated oral AAS) |
| Legal/regulatory status (US) | IND/compounded; not FDA-approved for this indication as of 2026 | FDA-approved for hypogonadism | Most are research compounds; some banned by FDA in 2024-2025 | Schedule III controlled substance |
| Where this compound loses | Smaller T peak than TRT; requires functional testes; less data on long-term use | Fertility; long-term cardiovascular data mixed | Weaker than exogenous HGH or steroids for body composition | Legal risk, liver stress, HPG suppression, virilization in women |
Operational Guide: How to Read a COA and Judge a Product
What a real COA must contain
- Purity by HPLC: for injectable-grade peptides, look for greater than 98% purity. Research-grade is often 95%+. Below 95% means more impurities, including deletion sequences that can be immunogenic.
- Molecular weight confirmation: mass spectrometry (MS) confirming the expected molecular weight of the peptide. This verifies the correct amino acid sequence was synthesized.
- Lot number on both the COA and the vial: if these do not match, the COA may not correspond to what you have.
- Issuing lab is independent: an in-house COA from the same company that manufactured the product is weaker evidence than one from a named third-party analytical chemistry lab.
- For compounded injectables: endotoxin (LAL test) and sterility testing results. These are required for any sterile preparation. Absence is a red flag for compounding pharmacies; research chemical vendors typically do not provide these, which is a meaningful risk difference.
Reconstitution math example
A 5 mg vial of ipamorelin reconstituted with 2 mL bacteriostatic water yields a concentration of 2.5 mg/mL = 2500 mcg/mL. A 200 mcg dose requires 0.08 mL = 8 units on a 100-unit insulin syringe. Confirm your syringe markings before drawing. Errors here directly affect whether results match expectations.
What degraded peptide looks like
Reconstituted peptide should be clear and colorless. Cloudiness, particulates, or yellow-brown discoloration suggest bacterial contamination, oxidation, or aggregation. Discard and do not inject. Lyophilized powder should be a white to off-white fluffy cake. A collapsed or tan powder suggests moisture intrusion during storage or manufacturing.
Frequently Asked Questions
What before-and-after results can I realistically expect from enclomiphene?
In RCTs, enclomiphene raises total testosterone from hypogonadal ranges into the normal adult male range within 3 to 6 weeks while preserving sperm production. Subjective symptom changes lag lab improvements by several weeks and are variable.
How long does enclomiphene take to show results?
LH and FSH rise within days. Total testosterone reaches new steady-state levels within 3-6 weeks. Symptom relief often takes 6-12 weeks because tissue adaptation lags the hormonal shift.
What before-and-after results do peptide injections produce?
Results depend on the specific peptide. GHRP/GHRH class peptides raise overnight GH pulse amplitude measurably but body composition changes in human studies are modest, roughly 1-2 kg lean mass and modest fat reduction over 3-6 months at best.
What do 2 IU HGH per day results look like over 6 months?
Clinical GHD replacement trials using roughly 1-2 IU/day show meaningful visceral fat reduction, modest lean mass gains, and improved lipid profiles over 6-12 months. These studies enrolled growth hormone deficient adults; results in healthy adults are smaller and carry more risk.
Are peptide before-and-after photos on social media reliable?
No. They are not controlled, not blinded, and frequently confounded by simultaneous diet, training, other compounds, lighting, and selection bias. They represent individual anecdote, not evidence.
How does enclomiphene compare to TRT for before-and-after outcomes?
TRT raises testosterone faster and higher and produces larger short-term body composition shifts, but suppresses endogenous production and fertility. Enclomiphene preserves fertility and testicular volume. The right choice depends on individual goals and baseline.
What results does Anavar produce versus peptides?
Anavar is an anabolic steroid with significantly stronger lean-mass and strength effects than any approved peptide, but it suppresses the HPG axis, carries hepatotoxicity risk, and is a Schedule III controlled substance.
What is the biggest failure mode people miss with peptide injection results?
Peptide degradation before injection. Many peptides lose potency rapidly if stored improperly, reconstituted incorrectly, or sourced from vendors without third-party COAs. Poor results may reflect an inactive product, not a protocol failure.
Can I judge a peptide product's quality from the label?
Partially. Look for: peptide stated in mg, a lot number, and a COA from an independent HPLC lab showing purity above 98%. For injectable use, endotoxin and sterility testing results should also be present.
Do HGH peptides produce the same results as recombinant HGH?
No. GH secretagogues stimulate endogenous GH release and are subject to the body's negative feedback limits. They cannot produce supraphysiologic GH levels the way exogenous recombinant HGH can, which means both smaller results and a safer risk profile.
What timeline should I expect for body composition changes with peptide injections?
Measurable body composition changes in human studies typically require a minimum of 8-12 weeks of consistent dosing. Most rigorous GH secretagogue trials run 3-6 months to detect statistically significant changes.
Sources
- Wiehle RD, et al. "Enclomiphene citrate stimulates serum testosterone and maintains sperm concentration in men with secondary hypogonadism." Urology. 2014;84(6):1384-1388.
- Kim ED, et al. "Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone." Fertility and Sterility. 2013;100(1):247-254.
- Walker RF, et al. Early human pharmacokinetic and pharmacodynamic studies of CJC-1295 demonstrating dose-dependent GH and IGF-1 increases in healthy adults. (Published research on CJC-1295 human PK/PD; consult primary literature for specific journal and volume details.)
- Falutz J, et al. "Metabolic effects of a growth hormone-releasing factor in patients with HIV." New England Journal of Medicine. 2007;357(23):2359-2370. (Tesamorelin RCT basis for FDA approval.)
- GH Research Society. "Consensus Guidelines for the Diagnosis and Treatment of Adults with Growth Hormone Deficiency." Journal of Clinical Endocrinology and Metabolism. 2007;92(11):4141-4153.
- Molitch ME, et al. "Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline." Journal of Clinical Endocrinology and Metabolism. 2011;96(6):1587-1609.
- Arwert LI, et al. "Effects of 10 years of growth hormone replacement therapy in adult GH-deficient men." Clinical Endocrinology. 2005;63(3):310-316.
- FDA Drug Safety Communication regarding compounded GH secretagogues. FDA.gov. 2024-2025 guidance updates.
Footer Disclaimers
Platform disclaimer: FormBlends is an informational platform. Nothing on this page constitutes medical advice, diagnosis, or treatment. Consult a qualified physician before starting any hormonal, peptide, or research compound protocol.
Research compound or compounded medication disclaimer: Several compounds discussed on this page, including enclomiphene as a standalone medication and most GH-releasing peptides, are either research compounds, compounded medications, or investigational drugs without full FDA approval for the indications discussed. Regulatory status varies by jurisdiction and changes over time. Verify current status with a licensed prescriber.
Results disclaimer: Individual results vary substantially based on baseline hormone levels, genetics, diet, training, sleep, and adherence. Results depicted in social media content or testimonials referenced on this page are not typical and are not endorsed by FormBlends.
Trademark disclaimer: Anavar is a trademark of Pfizer. Clomiphene citrate, enclomiphene, tesamorelin, and all other compound names are used descriptively. FormBlends has no affiliation with manufacturers of these compounds.